NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Telomir Pharmaceuticals, Inc. (TELO) Stock Analysis

Telomir Pharmaceuticals, Inc. (TELO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TELO

$1.16

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TELO with… →

TELO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.17
Previous Close
$1.16
Day's Range
1.16–1.19
52-Week Range
0.89–2.09
Volume
33.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.25
Valuation
Market Cap
$79.78M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.10
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$10.41M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.77M
1-Year Return
−6.45%
Dividend and dates
Avg Volume
95.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TELO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.78%
2025−67.72%
2024 (partial year)−17.60%

As of September 4, 2026.

TELO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$10.41M—
2024$0.00−$16.53M—
2023$0.00−$13.07M—
2022$0.00−$854.15K—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$10.54M−$10.41M—
2024$0.00—−$12.24M−$16.53M—
2023$0.00—−$3.94M−$13.07M—
2022$0.00—−$854.15K−$854.15K—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TELO Valuation vs Biotechnology Median

Median of 656 stocks
MetricTELOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Telomir Pharmaceuticals, Inc. (TELO) at $79.78M. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for TELO is $1.16, dated September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.89 to $2.09. The latest close sits 30.63% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $10.41M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −6.45%. The stored price history starts on February 9, 2024, and the total return since then is −76.80%. Beta against the wider market is reported at −0.25. Annualized volatility over the trailing 2 years is 109.22%.

Growth & Income

The record shows no dividend for TELO.

The record holds one complete calendar year, 2025, which returned −67.72%. So far in 2026 the price is −12.78%.

Peer Comparison

Telomir Pharmaceuticals, Inc. (TELO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Telomir Pharmaceuticals, Inc. TELO $79.78M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Telomir Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Visit website →